These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16269972)

  • 1. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients.
    González A; López B; Martín-Raymondi D; Lozano E; Varo N; Barba J; Serrano M; Díez J
    J Hypertens; 2005 Dec; 23(12):2297-304. PubMed ID: 16269972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?
    López B; González A; Lasarte JJ; Sarobe P; Borrás F; Díaz A; Barba J; Tomás L; Lozano E; Serrano M; Varo N; Beloqui O; Fortuño MA; Díez J
    J Hypertens; 2005 Mar; 23(3):625-32. PubMed ID: 15716706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension.
    López B; Castellano JM; González A; Barba J; Díez J
    Hypertension; 2007 Nov; 50(5):977-83. PubMed ID: 17846346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications.
    López B; González A; Querejeta R; Barba J; Díez J
    J Hypertens; 2009 Feb; 27(2):418-24. PubMed ID: 19155793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
    Pouleur AC; Uno H; Prescott MF; Desai A; Appelbaum E; Lukashevich V; Smith BA; Dahlöf B; Solomon SD;
    J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):483-90. PubMed ID: 21746765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
    J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical importance of detecting exaggerated blood pressure response to exercise on antihypertensive therapy.
    Mizuno R; Fujimoto S; Saito Y; Yamazaki M
    Heart; 2016 Jun; 102(11):849-54. PubMed ID: 26839069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension.
    Assadi F
    Pediatr Cardiol; 2007; 28(1):27-33. PubMed ID: 17308944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of phagocytic NADPH oxidase activity with hypertensive heart disease: a role for cardiotrophin-1?
    Moreno MU; San José G; Pejenaute Á; Landecho MF; Díez J; Beloqui Ó; Fortuño A; Zalba G
    Hypertension; 2014 Mar; 63(3):468-74. PubMed ID: 24324051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
    Ketelhut S; Franz IW; Ketelhut RG
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular hypertrophy in nondiabetic predialysis CKD.
    Paoletti E; Bellino D; Cassottana P; Rolla D; Cannella G
    Am J Kidney Dis; 2005 Aug; 46(2):320-7. PubMed ID: 16112052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network).
    Lønnebakken MT; Izzo R; Mancusi C; Gerdts E; Losi MA; Canciello G; Giugliano G; De Luca N; Trimarco B; de Simone G
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28275070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy: a meta-analysis of randomized controlled trials.
    Zhang K; Chen J; Liu Y; Wang T; Wang L; Wang J; Huang H
    J Hum Hypertens; 2013 Nov; 27(11):698-706. PubMed ID: 23535988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension.
    Pierdomenico SD; Lapenna D; Cuccurullo F
    Am J Hypertens; 2008 Apr; 21(4):464-70. PubMed ID: 18369364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
    Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
    Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
    Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of left ventricular hypertrophy in patients with essential hypertension. Results of 6 month treatment with indapamide.
    Curry CL; Robinson H; Brown R; Olivan J; Sami M; Honos G; Ruddy TD; Balazovjech I; Touzek F; Galinier F; Mariani M; de Cordoüe A; Barrandon S; Brault Y; Guez D
    Am J Hypertens; 1996 Aug; 9(8):828-32. PubMed ID: 8862231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antihypertensive therapy on left ventricular hypertrophy of essential hypertension: a role for insulin-like growth factor I?
    Díez J; Laviades C; Mayor G
    J Hum Hypertens; 1993 Oct; 7(5):479-84. PubMed ID: 8263889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.